文献速递胸部肿瘤

小细胞肺癌患者列线图预后模型的开发与验证

Development and Validation of a Nomogram Prognostic Model for SCLC Patients.
PubMed 文献 · J Thorac Oncol · 2018-06-11

研究基于美国国家癌症数据库(NCDB)2004—2011年确诊的24,680例SCLC患者数据开发列线图预后模型,并在2012—2013年确诊的9,700例独立队列中验证。模型纳入年龄、性别、种族、族裔、Charlson/Deyo评分、AJCC第八版TNM分期、治疗方式及侧别,验证队列一致性指数为0.722±0.004、积分AUC为0.79,预后准确性显著优于包括AJCC第八版TNM分期在内的既往模型。

要点

  • 列线图纳入年龄、性别、种族、族裔、合并症评分、TNM分期、治疗方式与侧别。
  • 独立验证队列一致性指数0.722±0.004、积分AUC 0.79。
  • 模型准确性显著优于既往模型及AJCC第八版TNM分期。

核心结论

  • 基于NCDB大队列开发并独立验证的SCLC列线图预后模型,预后准确性优于既往模型及AJCC第八版TNM分期系统。

研究设计与样本

  • 利用NCDB 2004—2011年确诊的24,680例SCLC患者数据开发列线图预后模型。
  • 采用2012—2013年确诊的9,700例SCLC患者独立队列进行验证。
  • 以p值、一致性指数及时间依赖ROC曲线积分AUC评价预后性能。

主要发现

  • 最终模型纳入年龄、性别、种族、族裔、Charlson/Deyo评分、AJCC第八版TNM分期、治疗类型(手术、放疗、化疗组合)及侧别。
  • 验证队列一致性指数为0.722±0.004,积分AUC为0.79。
  • 模型预后准确性显著高于既往开发的模型,包括AJCC第八版TNM分期系统。
  • 已将所提列线图与四个既往发表的列线图部署于在线网络服务器。

临床怎么用

  • 可借助该列线图对SCLC患者进行风险分层与治疗规划,并为临床试验入组标准提供参考。
  • 模型已上线网络服务器,便于临床计算与比较既往列线图。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: SCLC accounts for almost 15% of lung cancer cases in the United States. Nomogram prognostic models could greatly facilitate risk stratification and treatment planning, as well as more refined enrollment criteria for clinical trials. We developed and validated a new nomogram prognostic model for SCLC patients using a large SCLC patient cohort from the National Cancer Database (NCDB). METHODS: Clinical data for 24,680 SCLC patients diagnosed from 2004 to 2011 were used to develop the nomogram prognostic model. The model was then validated using an independent cohort of 9700 SCLC patients diagnosed from 2012 to 2013. The prognostic performance was evaluated using p value, concordance index and integrated area under the (time-dependent receiver operating characteristic) curve (AUC). RESULTS: The following variables were contained in the final prognostic model: age, sex, race, ethnicity, Charlson/Deyo score, TNM stage (assigned according to the American Joint Committee on Cancer [AJCC] eighth edition), treatment type (combination of surgery, radiation therapy, and chemotherapy), and laterality. The model was validated in an independent testing group with a concordance index of 0.722 ± 0.004 and an integrated area under the curve of 0.79. The nomogram model has a significantly higher prognostic accuracy than previously developed models, including the AJCC eighth edition TNM-staging system. We implemented the proposed nomogram and four previously published nomograms in an online webserver. CONCLUSIONS: We developed a nomogram prognostic model for SCLC patients, and validated the model using an independent patient cohort. The nomogram performs better than earlier models, including models using AJCC staging.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Wang S, Yang L, Ci B, et al. Development and Validation of a Nomogram Prognostic Model for SCLC Patients. J Thorac Oncol. 2018. PMID: 29902534. doi:10.1016/j.jtho.2018.05.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。